US2007099991A1PendingUtilityA1
Selective rxr ligands
Individually held — no corporate assignee on recordPriority: Sep 25, 2001Filed: Dec 21, 2006Published: May 3, 2007
Est. expirySep 25, 2021(expired)· nominal 20-yr term from priority
A61P 3/06A61P 9/12A61P 5/10A61P 37/08A61P 5/14A61P 37/02A61P 3/10A61P 9/00A61P 5/16A61P 37/06A61P 5/06A61P 25/16A61P 25/28A61P 27/02A61P 35/02A61P 3/04A61P 35/00A61P 31/22A61P 29/00A61P 31/04A61P 17/02A61P 17/14C07D 409/04A61P 17/06A61P 17/12C07D 307/54C07D 263/56C07D 333/60C07D 333/24A61P 17/00A61P 17/16A61P 1/04C07D 491/04A61P 17/10A61P 15/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα, RXRβ, or RXRγ. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.
Claims
exact text as granted — not AI-modified1 . A compound selected from the group consisting of:
(2E)-3-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-benzofuran-2-yl]-2-propenoic acid; (2E)-3-(4-{[(2,6,6-trimethylcyclohexen-1-yl)methyl]amino}benzofuran-2-yl)-2-propenoic acid; (2E)-3-{4-[4-Dimethylamino)-3-ethylphenyl]-4,5,6,7-tetrahydro-1-benzofuran-2-yl}-2-propenoic acid; (2E)-3-{4-[(E)-2-(2,6,6-Trimethyl-1-cyclohexen-1-yl)ethenyl]-1-benzofuran-2-yl}-2-propenoic acid; or salts, solvates, or pharmaceutically functional derivatives thereof.Join the waitlist — get patent alerts
Track US2007099991A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.